GeneDx Holdings (WGS) Change in Receivables (2020 - 2026)

GeneDx Holdings (WGS) has reported Change in Receivables for 7 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Receivables fell 70.11% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $30.2 million (up 68.36% YoY), while the FY2025 annual figure was $36.2 million, up 599.44% from the prior year.
• Change in Receivables fell to $2.6 million in Q1 2026 per WGS's latest filing, from $13.4 million in the prior quarter.
• Across five years, Change in Receivables topped out at $13.4 million in Q4 2025 and bottomed at -$13.5 million in Q2 2022.
• Historically, Change in Receivables has averaged $1.6 million across 5 years, with a median of -$36000.0 in 2022.
• On a YoY basis, Change in Receivables climbed as much as 2359.42% in 2024 and fell as far as 435.0% in 2024.
• GeneDx Holdings' Change in Receivables stood at -$36000.0 in 2022, then jumped by 655.56% to $200000.0 in 2023, then slumped by 435.0% to -$670000.0 in 2024, then jumped by 2104.78% to $13.4 million in 2025, then plunged by 80.96% to $2.6 million in 2026.
• Business Quant data shows WGS's Change in Receivables at $2.6 million in Q1 2026, $13.4 million in Q4 2025, and $12.9 million in Q3 2025.